Business, energy, technology, markets and global industry news from Business News Today

China biotech

PharmaDeviceNews China biotech
Representative image of scientists reviewing oncology research data in a modern biopharma laboratory, reflecting Pfizer and Innovent Biologics’ $10.5 billion collaboration and the growing race to develop antibody-drug conjugates and multispecific cancer therapies.
Pharma & Biotech

Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?

Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.

Read More
Representative image of pharmaceutical executives and scientists reviewing drug discovery data in a modern research setting, reflecting Eli Lilly and Haisco Pharmaceutical’s multi-program collaboration and the growing role of China-originated innovation in global pharma licensing.
Pharma & Biotech

Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?

Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.

Read More
Representative image of oncology researchers reviewing molecular therapy data, reflecting Pfizer and Innovent Biologics’ global collaboration to advance antibody-drug conjugates, multispecific antibodies, and next-generation cancer medicines.
Pharma & Biotech

Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines

Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?

Read More
Pharma & Biotech

Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset

Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.

Read More
Pharma & Biotech

With AlloJoin Phase 3 in motion, Fosun Kairos takes lead on stem cell therapy rollout in China

ElpasBio partners with Fosun Kairos to commercialize AlloJoin stem cell therapy for KOA in China. Find out what this deal means for the cell therapy market.

Read More
Pharma & Biotech

Innovent’s mazdutide earns Nature spotlight: Are dual GCG/GLP-1 agonists set to reshape diabetes and obesity care?

Innovent Biologics, Inc. has achieved a landmark moment in China’s clinical research trajectory with the back-to-back publication of two Phase 3 clinical trials of mazdutide, a dual GCG/GLP-1 receptor agonist, in Nature as Accelerated Article Previews. These studies, known as DREAMS-1 and DREAMS-2, evaluated the drug as monotherapy and as an add-on therapy in Chinese

Read More
Medical Devices & Diagnostics

Can Sanyou Biopharmaceuticals and KanryBio Biotechnology disrupt the global companion diagnostics market?

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Wenzhou KanryBio Biotechnology Co., Ltd. have entered into a strategic collaboration focused on co-developing high-value reagents and products for biomarker assay kits. Announced on December 10, 2025, this partnership aims to combine Sanyou Biopharmaceuticals’ global leadership in AI-driven molecular discovery with KanryBio Biotechnology’s capabilities in kit product development and

Read More